# Barrett Esophagus

Manage Barrett esophagus by confirming intestinal metaplasia and dysplasia with high-quality endoscopy and expert pathology, then selecting surveillance or eradication therapy according to dysplasia grade, visible lesions, and procedural fitness.

**Clinical question:** How should Barrett esophagus be screened, sampled, risk-stratified, treated, and surveilled according to dysplasia status?

Updated: 2026-09-16T00:42:55.859852+00:00

## What matters in practice
- Screen once with upper endoscopy in chronic GERD plus at least 3 additional risk factors: male sex, age over 50 years, White race, tobacco smoking, obesity, or a first-degree relative with Barrett esophagus or esophageal adenocarcinoma. [14]
- At surveillance, inspect with high-definition white light and chromoendoscopy, biopsy every visible lesion separately, and use systematic 4-quadrant Seattle biopsies. [14][18]
- Have any diagnosis of Barrett dysplasia confirmed by a second gastrointestinal pathologist before changing surveillance or performing eradication therapy. [14][18]
- Do not perform routine endoscopic eradication therapy for nondysplastic Barrett esophagus; surveillance is the preferred approach. [5][20]
- For confirmed low-grade dysplasia, radiofrequency ablation is favored after reproducible dysplasia on biopsies from 2 endoscopies and confirmation by 2 gastrointestinal pathologists. [1][18]
- A visible nodular lesion requires endoscopic resection before ablation of residual Barrett mucosa; high-grade dysplasia generally warrants endoscopic eradication rather than surveillance alone. [2][18]

## Who should undergo screening endoscopy?

Use risk-enriched screening rather than endoscopy for reflux symptoms alone.

Offer a single screening endoscopy to patients with chronic GERD symptoms who also have 3 or more additional Barrett esophagus risk factors: male sex, age greater than 50 years, White race, tobacco smoking, obesity, or a first-degree family history of Barrett esophagus or esophageal adenocarcinoma. [14]

Do not place patients with an irregular Z-line or columnar-lined esophagus shorter than 1 cm into a Barrett surveillance program. AGA guidance conditionally recommends against surveillance for columnar-lined esophagus shorter than 1 cm, and NICE recommends no surveillance for confirmed short-segment Barrett esophagus under 3 cm without intestinal metaplasia after 2 endoscopies. [8][18]

During diagnostic endoscopy, document Barrett extent with the Prague C&M classification and obtain at least 8 biopsies when endoscopic findings suggest Barrett esophagus; use the Seattle protocol for segments longer than 4 cm. [14]
- Define the distal Barrett landmark at the proximal gastric folds; report circumferential and maximal extent separately with Prague C&M criteria. [16]
- Sample any nodule, ulcer, mass, or other mucosal irregularity separately because visible abnormalities have increased likelihood of dysplasia or early cancer. [15]
- Control reflux-related inflammation before surveillance biopsies when feasible, because reactive atypia can confound dysplasia interpretation. [17]

*Screening and diagnostic decisions in suspected Barrett esophagus. [14][18]*

| Endoscopic or clinical finding | Interpretation | Next action |
| --- | --- | --- |
| Chronic GERD plus 3 or more specified risk factors | Risk-enriched candidate for screening. [14] | Perform one screening upper endoscopy. [14] |
| Columnar mucosa <1 cm or irregular Z-line | Does not warrant routine Barrett surveillance. [8] | Do not enroll in surveillance solely for this finding. [8] |
| Possible Barrett mucosa at screening | Histology is needed to establish intestinal metaplasia. [14] | Obtain at least 8 biopsies; use Seattle sampling for segments >4 cm. [14] |
| Visible lesion within Barrett segment | Higher-risk focal neoplasia must be excluded. [15] | Target and separately label biopsies; if neoplasia is identified, plan endoscopic resection for visible lesions. [2] |

## How to perform surveillance and validate dysplasia

Surveillance quality determines whether dysplasia classification is actionable.

Use high-resolution white-light endoscopy plus chromoendoscopy, including virtual chromoendoscopy, for Barrett surveillance. Perform targeted biopsies from visible lesions, then systematic 4-quadrant biopsies every 2 cm in patients without prior dysplasia and every 1 cm when there is a history of dysplasia. [10][14]

The Seattle protocol consists of careful inspection, biopsy of visible lesions, and 4-quadrant biopsies at intervals no greater than 2 cm from the lower esophageal sphincter to the squamocolumnar junction. Its purpose is to reduce sampling error because dysplasia can be focal and endoscopically inconspicuous. [14]

Before labeling a patient low-grade dysplasia, high-grade dysplasia, or indefinite for dysplasia, obtain confirmation from a second pathologist with gastrointestinal pathology expertise. This is a strong ACG recommendation for dysplasia of any grade and is particularly consequential because the diagnosis determines whether the patient enters ablation therapy. [14]
- Use 1-cm rather than 2-cm 4-quadrant mapping in a dysplastic Barrett segment. [10][17]
- Biopsy the anatomic cardia separately during mapping surveillance when following the described protocol. [17]
- Post-eradication surveillance should examine both esophagus and cardia with white light, virtual chromoendoscopy, and near focus. [11]

### Indefinite for dysplasia

For indefinite dysplasia, optimize acid-suppressive therapy and repeat upper endoscopy with biopsies in 6 months. If repeat biopsies do not show definite dysplasia, revert to the nondysplastic Barrett surveillance strategy. [18][19]

*Biopsy strategy by Barrett dysplasia context. [10][14][17]*

| Clinical context | Inspection and biopsy approach | Actionable implication |
| --- | --- | --- |
| Nondysplastic Barrett surveillance | High-definition white light plus chromoendoscopy; targeted lesion biopsies plus 4-quadrant biopsies every 2 cm. [10][14] | Detect occult dysplasia while continuing surveillance-based management. [12] |
| Prior or suspected dysplasia | Target visible lesions and obtain 4-quadrant biopsies every 1 cm. [10][17] | Confirm grade with expert gastrointestinal pathology before treatment selection. [14] |
| Indefinite for dysplasia | Optimize acid suppression and repeat endoscopy at 6 months. [18][19] | Definite dysplasia redirects to eradication therapy planning; no definite dysplasia redirects to nondysplastic surveillance. [19] |

## Choose surveillance or eradication therapy by dysplasia grade and lesion morphology

Visible lesions require resection-first management; flat dysplasia is generally treated with ablation.

For nondysplastic Barrett esophagus, use endoscopic surveillance rather than routine endoscopic eradication therapy. RFA is not suggested for the general population without dysplasia because comparative evidence has not established a superior net health outcome over surveillance. [5][20]

For confirmed low-grade dysplasia, discuss endoscopic eradication therapy versus surveillance, but favor RFA when dysplasia is confirmed on biopsies from 2 separate endoscopies and by 2 gastrointestinal pathologists. Randomized evidence shows RFA improves complete eradication of dysplasia and intestinal metaplasia compared with surveillance and shows benefit for progression to high-grade dysplasia or cancer, although progression estimates are imprecise. [1][18][21]

For high-grade dysplasia, proceed with endoscopic eradication therapy rather than surveillance as first-line management. If a visible lesion is present, perform endoscopic resection, typically EMR, for staging and therapy, then ablate residual Barrett mucosa. NICE specifically recommends ablation of residual Barrett esophagus after endoscopic resection for high-grade dysplasia. [2][18]
- Use EMR for a visible nodular lesion or early esophageal adenocarcinoma rather than primary ablation of that lesion. [2][3]
- Use RFA as the established ablation modality for dysplastic Barrett esophagus; cryotherapy and photodynamic therapy may be alternatives or adjuncts when resection is unsuitable or another modality is needed. [6]
- Refer long-segment Barrett esophagus of 10 cm or more to an expert Barrett center. [3]

### Early adenocarcinoma detected in Barrett mucosa

Treat visible early neoplasia with endoscopic resection to obtain histologic staging and determine whether endoscopic therapy can be curative. Endoscopic resection is first-line curative treatment for well or moderately differentiated T1a esophageal adenocarcinoma in cited guideline summaries; residual Barrett mucosa should then be eradicated to reduce metachronous neoplasia risk. [4][18]

*Management branch after expert confirmation of Barrett histology. [1][2][5][18][20]*

| Histology or endoscopic phenotype | Preferred next step | Key exception or prerequisite |
| --- | --- | --- |
| Nondysplastic Barrett esophagus | Endoscopic surveillance. [5] | Do not use routine eradication therapy in the general nondysplastic population. [20] |
| Indefinite for dysplasia | Optimize acid suppression; repeat endoscopy in 6 months. [18] | If repeat biopsies lack definite dysplasia, follow nondysplastic surveillance strategy. [19] |
| Confirmed low-grade dysplasia | Offer or strongly consider RFA after confirmation on 2 endoscopies and by 2 GI pathologists. [18] | Surveillance remains a reasonable alternative in selected patients. [5] |
| High-grade dysplasia without visible lesion | Endoscopic eradication therapy, commonly RFA. [2][3] | Surveillance is not generally first-line management. [3] |
| High-grade dysplasia or early cancer with visible lesion | Endoscopic resection first, followed by eradication of residual Barrett mucosa. [2][18] | Do not rely on ablation alone for a visible lesion. [2] |

## Maintain surveillance after eradication and do not use antireflux surgery for cancer prevention

Eradication reduces neoplastic burden but does not eliminate the need for endoscopic follow-up.

Arrange endoscopic follow-up after endoscopic treatment for Barrett esophagus with dysplasia. During post-eradication examinations, inspect the esophagus and cardia using white light, virtual chromoendoscopy, and near focus to identify recurrent Barrett mucosa or neoplasia. [11][18]

Continue long-term follow-up after apparent complete eradication because progression or recurrence can occur after endoscopic eradication therapy. [20]

Do not recommend fundoplication or other antireflux surgery solely to prevent esophageal adenocarcinoma in Barrett esophagus. In a cohort of 33,939 patients followed for up to 32 years, antireflux surgery was not associated with reduced adenocarcinoma risk versus antireflux medication (adjusted hazard ratio 1.9; 95% CI, 1.1-3.5). [8][23]
- Use antireflux surgery for conventional reflux indications rather than as a Barrett cancer-prevention intervention. [8][23]
- Tailor surveillance frequency within recommended intervals to age, sex, family history of esophageal cancer, and smoking history. [18]
- Reassess whether surveillance benefits outweigh procedural risks in patients with substantial comorbidity or limited physiologic reserve. [18]

*Longitudinal decisions after Barrett diagnosis or eradication. [8][11][18][20]*

| Clinical issue | Decision | Rationale |
| --- | --- | --- |
| After endoscopic treatment for dysplastic Barrett | Continue endoscopic follow-up. [18] | Progression or recurrence can occur after eradication therapy. [20] |
| Post-eradication examination | Inspect esophagus and cardia with white light, virtual chromoendoscopy, and near focus. [11] | Improve detection of recurrent mucosal abnormality. [11] |
| Considering fundoplication for cancer prevention | Do not offer solely to reduce adenocarcinoma risk. [8] | Long-term observational data did not show risk reduction compared with antireflux medication. [8][23] |

## Common questions

### Does a patient with an irregular Z-line require Barrett surveillance?

No. Columnar-lined esophagus shorter than 1 cm should not undergo routine Barrett surveillance; this finding should not be treated as a surveillance-eligible Barrett segment. [8]

### When should a visible Barrett lesion be ablated?

Do not use primary ablation for a visible nodular lesion. Perform endoscopic resection first for diagnosis, staging, and local therapy, then eradicate residual Barrett mucosa when indicated. [2][18]

## References
1. National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett’s oesophagus and stage I oesophageal adenocarcinoma | Gut — gut.bmj.com — https://gut.bmj.com/content/73/6/897
2. Utility of ancillary studies in the diagnosis and risk assessment of Barrett’s esophagus and dysplasia | Modern Pathology — www.nature.com — https://www.nature.com/articles/s41379-022-01056-0
3. Antireflux Surgery for Barrett&apos;s Esophagus: Where Do We Stand in Preventing Esophageal Adenocarcinoma? - Kollmann - 2026 - Annals of the New York Academy of Sciences - Wiley Online Library — nyaspubs.onlinelibrary.wiley.com — https://nyaspubs.onlinelibrary.wiley.com/doi/full/10.1111/nyas.70196
4. Barrett's Esophagus — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/jgh.70166
5. Endoscopic eradication therapy for Barrett's... : Current Opinion in ... — journals.lww.com — https://journals.lww.com/co-gastroenterology/fulltext/2020/07000/endoscopic_eradication_therapy_for_barrett_s.16.aspx?Ppt=Article%7Cco-gastroenterology%3A2020%3A07000%3A00016%7C10.1097%2Fmog.0000000000000650%7C
6. Advancements in interventional gastroenterology... : Medicine — journals.lww.com — https://journals.lww.com/md-journal/_layouts/15/oaks.journals/downloadpdf.aspx?an=00005792-202604240-00098
7. Barrett Esophagus - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/nursing-and-health-professions/barrett-esophagus
8. Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett’s Esophagus — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0016508523049806
9. Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma | Diseases of the Esophagus | Oxford Academic — academic.oup.com — https://academic.oup.com/dote/article-abstract/19/5/321/2419710
10. AGA Clinical Practice Guideline on Surveillance of Barrett's ... — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(25)06013-5/fulltext
11. AGA Clinical Practice Guideline on Endoscopic Eradication Therapy ... — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(24)00302-0/fulltext
12. Surveillance in Barrett's Esophagus: Challenges, Progress, ... — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(23)00103-8/abstract
13. American Gastroenterological Association Medical Position ... — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(11)00084-9/fulltext
14. Diagnosis and Management of Barrett’s Esophagus: An Updated ACG Guideline - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10259184
15. American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC3258495
16. Barrett’s Esophagus: An Updated Review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9858189
17. Towards screening Barrett’s oesophagus: current guidelines, imaging modalities and future developments — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7519897
18. Recommendations | Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management  | Guidance | NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ng231/chapter/Recommendations
19. [PDF] HTG345 Endoscopic radiofrequency ablation for Barrett's ... - NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/htg345/evidence/overview-final-pdf-366535981
20. [PDF] NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE — www.nice.org.uk — https://www.nice.org.uk/guidance/htg219/documents/endoscopic-radiofrequency-ablation-for-barretts-oesophagus-with-low-grade-dysplasia-or-no-dysplasia-overview2
21. [PDF] Barrett's oesophagus and stage 1 oesophageal adenocarcinoma — www.nice.org.uk — https://www.nice.org.uk/guidance/ng231/evidence/i-endoscopic-treatment-lowgrade-dysplasia-and-indefinite-dysplasia-pdf-409368094164
22. Barrett Esophagus: Risk Factors for Progression to Dysplasia and Adenocarcinoma - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1357704
23. Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/37690771
24. Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma | WHO FCTC — portal-uat.who.int — https://portal-uat.who.int/fctcapps/fctcapps/fctc/kh/wts/wts-database/microbiome-and-potential-targets-chemoprevention-esophageal

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.